Experimental Treatment for Patients with Multiple Myeloma

Selinexor and Backbone Treatments of Multiple Myeloma Patients

This study will independently assess the efficacy and safety of six combination therapies for the treatment of patients with Relapsed/Refractory Multiple Myeloma (RR MM) and Newly Diagnosed Multiple Myeloma (NDMM). The combinations to be evaluated include: selinexor + pomalidomide + dexamethasone (SPd), selinexor + bortezomib + dexamethasone (SVd), selinexor + lenalidomide + dexamethasone (SRd), selinexor + pomalidomide + dexamethasone + bortezomib (SPVd), selinexor + daratumumab + dexamethasone (SDd), and selinexor + carfilzomib + dexamethasone (SKd). The abbreviations for combination treatments have been revised to use V (Velcade) for bortezomib, R (Revlimid) for lenalidomide, D (Darzalex) for daratumumab, and K (Kyprolis) for carfilzomib.

Pharmaceutical medication involved
Recruiting patients only

Drug - Selinexor


Drug - Dexamethasone

Oral tablets in a multi-dose vial.

Drug - Lenalidomide

25 mg Oral capsule

Drug - Pomalidomide

4 mg oral tablets

Drug - Bortezomib

3.5 mg for injection supplied as lyophilized powder in single-use viles for subcutaneous injection.

Drug - Daratumumab

16 mg/kg Intravenous

Drug - Carfilzomib

56 mg/m2 Intravenous

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma